Literature DB >> 33727019

Prognostic Value of Natural Killer Cells Besides Tumor-Infiltrating Lymphocytes in Breast Cancer Tissues.

Lobna Bouzidi1, Hana Triki2, Slim Charfi3, Wala Ben Kridis4, Mohamed Derbel5, Lobna Ayadi3, Tahya Sellami-Boudawara3, Boutheina Cherif2.   

Abstract

BACKGROUND: Each subgroup of immune cells has a different prognostic role in breast cancer; however, the prognostic impact of tumor-infiltrating natural killer cells (TINKs) is still not well established. Our aim was to assess the prognostic impact of natural killer (NK) cells in breast carcinomas.
MATERIALS AND METHODS: NK cells infiltration were assessed by immunohistochemistry (IHC). Statistical analyses were performed to evaluate the correlation of NK cells with clinical-pathological features and outcome.
RESULTS: CD56 IHC was realized in 126 patients. NK cells infiltration showed significant and positive association with tumor high Scarff-Bloom-Richardson (SBR) grade. NK cells were significantly associated with HER2-positive breast cancer and triple-negative breast cancer subtypes. Analyses showed significant and inverse correlation with progesterone and estrogen receptors expression status. High NK cells were significantly related to high Ki-67 labeling index. Our data showed that high NK cells infiltrate was significantly associated with tumor-infiltrating lymphocytes in breast cancer tissues. At a median follow-up of 5.5 years, high CD56 expression (≥ 5 cells/10 high power field) was associated significantly with a good overall survival and with good disease-free survival.
CONCLUSION: In this study, we assessed the important prognostic role of TINKs in breast carcinomas, which seems to be evident despite its association with aggressive pathological features. Thus evaluation of NK cells can be standardized and integrated in daily routine.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; CD56; Immune microenvironment; Natural killer cells; Prognosis; Tumor infiltrating lymphocytes

Mesh:

Substances:

Year:  2021        PMID: 33727019     DOI: 10.1016/j.clbc.2021.02.003

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  7 in total

1.  Pan-cancer analysis of tumor mutation burden sensitive tumors reveals tumor-specific subtypes and hub genes related to immune infiltration.

Authors:  Huan Wu; Hanchu Wang; Yue Chen
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-02       Impact factor: 4.553

2.  Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score.

Authors:  Hongxiao Li; Jigang Wang; Zaibo Li; Melad Dababneh; Fusheng Wang; Peng Zhao; Geoffrey H Smith; George Teodoro; Meijie Li; Jun Kong; Xiaoxian Li
Journal:  Front Med (Lausanne)       Date:  2022-06-14

Review 3.  Natural killer cell homing and trafficking in tissues and tumors: from biology to application.

Authors:  Guang He Ran; Yu Qing Lin; Lei Tian; Tao Zhang; Dong Mei Yan; Jian Hua Yu; You Cai Deng
Journal:  Signal Transduct Target Ther       Date:  2022-06-29

4.  Cross-Platform in-silico Analyses Exploring Tumor Immune Microenvironment with Prognostic Value in Triple-Negative Breast Cancer.

Authors:  Victor C Kok; Charles C N Wang; Szu-Han Liao; De-Lun Chen
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-04-12

5.  The prognostic value of MKL1 in predicting breast cancer immune infiltrates and chemosensitivity.

Authors:  Yijia Hua; Mengzhu Yang
Journal:  Bosn J Basic Med Sci       Date:  2022-06-01       Impact factor: 3.759

6.  An Injectable Epigenetic Autophagic Modulatory Hydrogel for Boosting Umbilical Cord Blood NK Cell Therapy Prevents Postsurgical Relapse of Triple-Negative Breast Cancer.

Authors:  Yihang Gong; Wenjie Chen; Xiuxing Chen; Yizhan He; Hua Jiang; Xijian Zhang; Lijie Pan; Beibei Ni; Fan Yang; Yan Xu; Qi Zhang; Lei Zhou; Yusheng Cheng
Journal:  Adv Sci (Weinh)       Date:  2022-06-16       Impact factor: 17.521

Review 7.  Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies.

Authors:  Barbara Seliger; Ulrike Koehl
Journal:  Front Immunol       Date:  2022-08-12       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.